BDBM166011 US10604504, Example 211::US11623921, Example 211::US9688629, 209::US9688629, 210::US9688629, 211::US9802915, Example 209::US9920031, Example 211

SMILES Cc1[nH]c2c(cc(F)c(-c3cccc4CN(CCc34)C(=O)C=C)c2c1C1CC1)C(N)=O

InChI Key InChIKey=NWOZQABVGNIQDF-UHFFFAOYSA-N

Data  15 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 15 hits for monomerid = 166011   

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM166011(US9688629, 209 | US9688629, 210 | US9688629, 211 |...)
Affinity DataIC50: 0.240nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM166011(US9688629, 209 | US9688629, 210 | US9688629, 211 |...)
Affinity DataIC50: 6.40nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM166011(US9688629, 209 | US9688629, 210 | US9688629, 211 |...)
Affinity DataIC50: 0.200nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM166011(US9688629, 209 | US9688629, 210 | US9688629, 211 |...)
Affinity DataIC50: 0.240nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM166011(US9688629, 209 | US9688629, 210 | US9688629, 211 |...)
Affinity DataIC50: 6.40nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM166011(US9688629, 209 | US9688629, 210 | US9688629, 211 |...)
Affinity DataIC50: 0.200nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM166011(US9688629, 209 | US9688629, 210 | US9688629, 211 |...)
Affinity DataIC50: 0.240nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/4/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM166011(US9688629, 209 | US9688629, 210 | US9688629, 211 |...)
Affinity DataIC50: 6.40nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/4/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM166011(US9688629, 209 | US9688629, 210 | US9688629, 211 |...)
Affinity DataIC50: 0.200nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/4/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM166011(US9688629, 209 | US9688629, 210 | US9688629, 211 |...)
Affinity DataIC50: 0.240nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM166011(US9688629, 209 | US9688629, 210 | US9688629, 211 |...)
Affinity DataIC50: 6.40nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM166011(US9688629, 209 | US9688629, 210 | US9688629, 211 |...)
Affinity DataIC50: 0.200nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM166011(US9688629, 209 | US9688629, 210 | US9688629, 211 |...)
Affinity DataIC50: 0.240nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM166011(US9688629, 209 | US9688629, 210 | US9688629, 211 |...)
Affinity DataIC50: 6.40nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM166011(US9688629, 209 | US9688629, 210 | US9688629, 211 |...)
Affinity DataIC50: 0.200nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2023
Entry Details
Go to US Patent